Subscribe to get Latest News Updates

Subscribe to get Latest News Updates

CWEB Inc.

Subscribe to get Latest News Updates

Subscribe to get Latest News Updates

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessModerna's Promising Developments and Analyst Optimism

Moderna’s Promising Developments and Analyst Optimism

Add to Favorite
Added to Favorite


Hartaj Singh of Oppenheimer sets a new price target for MRNA at $179, indicating a potential upside of about 20.63%.
Moderna’s experimental COVID-19-influenza combination vaccine, mRNA-1083, shows promising results in a late-stage study, potentially simplifying vaccination protocols.
The FDA approval of Moderna’s mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for adults aged 60 years and older, despite leading to a stock price decrease, underscores the company’s commitment to addressing respiratory diseases.

NASDAQ:MRNA, better known as Moderna, has recently been in the spotlight following a new price target set by Hartaj Singh of Oppenheimer. The target is set at $179, up from its current trading price of $148.39, suggesting a potential upside of about 20.63%. This optimistic outlook is based on Moderna’s promising developments and performance, as highlighted by TheFly. Moderna, a biotechnology company, has been at the forefront of vaccine development, particularly for its rapid development of the COVID-19 vaccine.
The company’s experimental COVID-19-influenza combination vaccine, mRNA-1083, has shown promising results, meeting its primary endpoints in a late-stage study. This vaccine demonstrated higher immune responses in older adults compared to the co-administered licensed flu and COVID vaccines. The study involved around 8,000 adults and showed that mRNA-1083 elicited stronger immune responses against influenza and COVID-19 than the current vaccines in use for these diseases. This development is significant as it marks a step forward in Moderna’s efforts to provide a combined solution for influenza and COVID-19, potentially simplifying vaccination protocols and enhancing public health outcomes.
Furthermore, Moderna’s recent FDA approval for its mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345), for adults aged 60 years and older underscores the company’s ongoing commitment to addressing respiratory diseases. Despite the vaccine’s efficacy rate of 78.7%, the announcement led to a notable decrease in Moderna’s stock price, which highlights the volatile nature of investing in biotech firms. This event has prompted an investigation by Bronstein, Gewirtz & Grossman, LLC into potential claims on behalf of Moderna investors, indicating the complex interplay between regulatory approvals, market expectations, and investor sentiment.
Currently, Moderna’s stock is trading at $148.39, with minor fluctuations observed in the trading session. The company’s market capitalization stands at approximately $56.87 billion, reflecting its significant position in the biotechnology industry. Despite the challenges, the advancements in vaccine development and the optimistic outlook from analysts suggest a promising future for Moderna. The company’s efforts to combine vaccines for influenza and COVID-19, along with its expansion into other respiratory diseases, position it as a key player in the ongoing fight against global health threats.

Subscribe to get Latest News Updates

Latest News

You may like more
more